Q-omics provides the consensus-scored DNAI2 profile across patient tissues and cancer cell-line models. DNAI2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, DNAI2 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, DNAI2 RNA expression shows 13,118 significant gene co-expression associations, with the highest sampling consensus in KIRC. Together, these results highlight SCLC, LUAD, and KIRC as cancer lineages where DNAI2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAI2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAI2 survival associations across molecular data types. DNAI2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAI2 RNA expression–survival associations across cancer types. High DNAI2 expression shows unfavorable associations in SCLC, MESO, OV and UVM, but favorable associations in LIHC and HNSC. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for DNAI2 RNA expression.
This table summarizes DNAI2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DNAI2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAI2 shows lower tumor expression in LUAD, THCA, LUSC, KICH and UCEC and higher tumor expression in KIRC. The LUAD box plot shows higher DNAI2 RNA expression in normal versus tumor tissue (log2 FC = −1.728, t-test p < 0.001).
This table shows molecular features associated with DNAI2 in patient tissues and cancer cell lines. In patient samples, DNAI2 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAI2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
